Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
14.80
-0.09 (-0.60%)
Nov 20, 2026, 11:47 AM EST - Market open
Aurinia Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Aurinia Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $18.5. The average 1-year stock price forecast is 25.00% higher than the current stock price, while the lowest is $16 (+8.11%) and the highest is $21 (+41.89%).
Price Target: $18.5 (+25.00%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Aurinia Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jul '26 | Aug '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bloom Burton | Bloom Burton | Buy Maintains $21 | Buy | Maintains | $21 | +41.89% | Nov 3, 2026 |
| RBC Capital | RBC Capital | Hold Reiterates $16 → $18 | Hold | Reiterates | $16 → $18 | +21.62% | Oct 30, 2026 |
| TD Cowen | TD Cowen | Buy Reiterates $17 → $18 | Buy | Reiterates | $17 → $18 | +21.62% | Oct 21, 2026 |
Financial Forecast
Revenue This Year
330.19M
from 283.06M
Increased by 16.65%
Revenue Next Year
388.73M
from 330.19M
Increased by 17.73%
EPS This Year
0.97
from 2.07
Decreased by -53.14%
EPS Next Year
1.16
from 0.97
Increased by 19.59%
EPS and Forward PE are based on non-GAAP adjusted numbers.